Shattuck Labs

Shattuck Labs is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a new class of biotherapeutics with multifunctional activity and potential applications in oncology and inflammatory diseases. Leveraging the ARC™ platform, Shattuck Labs is building a pipeline of therapeutic agents that integrate checkpoint blockade and TNF receptor agonists into single therapeutic drugs to improve patient outcomes. Shattuck Labs has offices in Austin, Texas, and Durham, North Carolina.